Open AccessAssociation Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab
Author(s) -
Nobuki Furubayashi,
Akinori Minato,
Takahito Negishi,
Naotaka Sakamoto,
Yu Song,
Yozo Hori,
Toshihisa Tomoda,
Mirii Harada,
Shingo Tamura,
Akihiro Miura,
Hiroki Komori,
Kentaro Kuroiwa,
Nobuhiko Seki,
Naohiro Fujimoto,
Motonobu Nakamura
Publication year - 2022
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s360473
Subject(s) - pembrolizumab , medicine , adverse effect , incidence (geometry) , eosinophil , gastroenterology , oncology , immunotherapy , cancer , physics , asthma , optics
To evaluate the association between immune-related adverse events (irAEs) and the clinical outcomes and also between irAEs and the post-treatment changes in the relative eosinophil count (REC) in advanced urothelial carcinoma (UC) patients treated with pembrolizumab.